BACKGROUND/AIM: @entity409 is a potential factor contributing to @entity5881 . @entity1068 depletes intestinal integrity and causes gut @entity6636 . @entity4876 , a fermentation byproduct of gut microbiota, is altered negatively following chronic @entity1068 exposure. This study aimed to determine whether prophylactic @entity18039 could protect the intestinal barrier and liver in @entity19 during combined chronic-binge @entity1068 exposure. METHODS: C57BL/6   J @entity19 exposed to 5% v/v @entity1068 -containing diet for 10   days received a single @entity1068 gavage (5   g/kg) 9   hrs prior to euthanasia. Control @entity19 were isocalorically pair-fed maltose dextrin for @entity1068 . Diets were supplemented (5   mM) with @entity18039 or @entity653 . Intestine and @entity409 activity was assessed histologically. Protein and mRNA expression of tight junction proteins (TJ), TLRs and @entity637 were assessed. Caco-2 monolayers with/without @entity1068 exposure and/or @entity4877 were used to test @entity4876 's direct effects on intestinal integrity. RESULTS: Chronic-binge @entity1068 feeding impaired intestinal TJ protein co-localization staining; however, @entity18039 co-treatment mitigated these effects. @entity1068 depleted TJ and transepithelial electrical resistance in Caco-2 monolayers, but @entity4876 co-treatment reduced these effects. Hepatic TLR mRNA expression and @entity637 protein expression was induced by @entity1068 ; however, the response was significantly dampened in @entity19 co-treated with @entity18039 . @entity18039 altered localization of both neutrophils and single hepatocyte death: leukocytes and apoptotic hepatocytes localized predominantly around the portal tract in @entity1068 -only treated @entity19 , whereas localization predominated around the central vein in @entity1068 - @entity18039 @entity19 . CONCLUSIONS: Prophylactic @entity18039 supplementation mitigated effects of combined chronic-binge @entity1068 exposure on disruption of intestinal TJ localization and intestinal permeability and @entity99 .

Prophylactic @entity18039 treatment mitigates chronic-binge alcohol-induced intestinal barrier and XXXX .

@entity4876 :: ('MESH:D002087', 'Chemical') :: ['Butyrate', 'butyrate'] @entity99 :: ('MESH:D056486', 'Disease') :: ['liver injury'] @entity5881 :: ('MESH:D008108', 'Disease') :: ['alcoholic liver disease'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity409 :: ('MESH:D008107', 'Disease') :: ['Impaired gut-liver axis', 'liver disease'] @entity6636 :: ('MESH:D064806', 'Disease') :: ['dysbiosis'] @entity653 :: ('MESH:D005990', 'Chemical') :: ['glycerol'] @entity4877 :: ('MESH:D020148', 'Chemical') :: ['sodium butyrate'] @entity18039 :: ('MESH:C005830', 'Chemical') :: ['Tributyrin', 'tributyrin'] @entity637 :: ('21926(Tax:10090)', 'Gene') :: ['TNFa'] @entity1068 :: ('MESH:D000431', 'Chemical') :: ['Ethanol', 'ethanol']
@entity99 :: (MESH:D056486,Disease) :: ['liver injury']
